Here are three things to know.
- Lucid launched the nationwide voluntary recall June 1 after receiving complaints from pharmacists about melted drug capsules.
- The recall applies to 30-count and 90-count bottles of the antidepressant.
- The Food and Drug Administration announced the recall last week, labeling it as a Class II event, meaning the quality issue poses an intermediate threat of illness or death.
More articles on supply chain:
Why this drugmaker invests in clean coal
FDA approves Shire’s ADHD drug: 3 things to know
Dr. Scott Gottlieb: FDA will ‘completely eliminate’ orphan drug backlog
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
